NCTU
Newcastle Neurosurgery Clinical Trials Unit

Neurosurgical Clinical Trial Unit
Neurosurgical Clinical Trial Unit - Clear IVH

click on the logo to go to the relevant external trial webpage

Clear IVH

Clear-IVH

International multi-centre trial to evaluate Recombinant Tissue Plasminogen Activator (rt-PA).

Clear-IVH is a multi-centre randomised controlled trial investigating rt-PA as a treatment for intraventricular haemorrhage thromobolysis and assessing clot removal and any changes in morbidity or mortality.


Brief inclusion / exclusion criteria
  • About Clear-IVH

Inclusion:

  • Age 18-75
  • IVC placesd as standard of care using 2 or less complete passes
  • Spontaneous ICH <30cc
  • Diagnosis <12 hours from onset
  • Able to receive first dose <48 hours of diagnostic CT
  • Clot size after 6 hours must be equal to the presentation clot size ± 5 cc (A*B*C)/2
  • 3rd or 4th ventricles are occluded with blood
  • Systolic blood pressure <200 mm Hg sustained for 6 hours
  • Historical of Rankin of 0 or 1


    • Exclusion:

  • Suspected or untreated aneurysm or AVM
  • Clotting disorders
  • Platelet count <105,PT>15s, INR >1.7 - reversal is allowed prior to enrollment
  • Raised APTT
  • Pregnancy
  • Infratentorial haemorrhage
  • Subarachnoid haemorrhage
  • Known risk for embolization
  • Prior enrollment in the study
  • Any other condition that pose a significant hazard if therapy was initiated
  • Participation in a simultaneous trial
    		•
    Staff Involved

    Principal Investigators:

    Prof. D. Hanley (USA)
    Dr. N. Naff

    Prof. A.D. Mendelow

    		 Assigned Registrar:

    European Monitor:

    Dr. B. Gregson

    IMASH


    Last updated 29 Jan 2008
    © NCTU
    Email: NCTU@ncl.ac.uk